Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses
Open Access
- 1 April 2009
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (4) , 697-706
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer TherapyMolecular Therapy, 2008
- Engineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune ResponseMolecular Therapy, 2007
- Inhibition of Retinoic Acid-Inducible Gene I-Mediated Induction of Beta Interferon by the NS1 Protein of Influenza A VirusJournal of Virology, 2007
- Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell LinesJournal of Virology, 2006
- Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle diseaseProceedings of the National Academy of Sciences, 2006
- Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor CellsCancer Research, 2004
- Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levelsCancer Gene Therapy, 2002
- NS1 Protein of Influenza A Virus Down-Regulates ApoptosisJournal of Virology, 2002
- Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancerCancer Immunology, Immunotherapy, 1992
- Interaction of Newcastle disease virus strains differing in virulence with chicken red blood cell receptorsArchives of Virology, 1985